Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn’s disease: a retrospective chart review

Background: Ustekinumab is a monoclonal antibody that inhibits interleukins 12 and 23. It is approved for treatment of Crohn’s disease (CD) in adults; however, there is a paucity of data regarding its use in pediatric CD. We describe our experience using ustekinumab in anti-TNF refractory CD pediatr...

Descripción completa

Detalles Bibliográficos
Autores principales: Do, Phinga, Andersen, John, Patel, Ashish, Semrin, Gaith, Sifuentes-Dominguez, Luis, Luu, Phuong, Gurram, Bhaskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408544/
https://www.ncbi.nlm.nih.gov/pubmed/34504690
http://dx.doi.org/10.12688/f1000research.22673.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408544/
https://www.ncbi.nlm.nih.gov/pubmed/34504690
http://dx.doi.org/10.12688/f1000research.22673.2

Ejemplares similares